Introduction {#s1}
============

*Mycobacterium tuberculosis* infection causes significant morbidity and mortality throughout the world, particularly in resource-poor countries. *M. tuberculosis* infects one third of the human population and approximately two million persons die of tuberculosis every year [@pone.0001388-1]. Over the next 20 years the WHO estimates that another billion people will become newly infected with *M. tuberculosis* and more than 25 million will die from the disease, despite the availability of antibiotics [@pone.0001388-Frieden1], [@pone.0001388-Flynn1]. In sub-Saharan Africa, the rates of tuberculosis range from 50 to greater than 300 per 100,000 individuals [@pone.0001388-Frieden1]. It is now well-established that there is a host genetic component to susceptibility to tuberculosis [@pone.0001388-Cooke1]. Evidence to support this includes the observation of familial clustering of disease with higher concordance of tuberculosis disease in monozygotic versus dizygotic twins [@pone.0001388-Comstock1], the ethnic clustering of tuberculosis disease with a higher prevalence of tuberculosis in individuals of recent African descent [@pone.0001388-Stead1], as well as the demonstration of both common polymorphisms and rare mutations which confer susceptibility to mycobacterial species in humans [@pone.0001388-Doffinger1].

Dendritic Cell-Specific ICAM3-Grabbing Non-integrin (DC-SIGN), encoded by *CD209* on chromosome 19p13.3, is a C-type lectin that is expressed on subsets of dendritic cells (DCs) and alveolar macrophages [@pone.0001388-Soilleux1]--[@pone.0001388-Tailleux2]. DC-SIGN has been demonstrated to bind a variety of ligands [@pone.0001388-Gordon1]; endogenous ligands include endothelial cells through ICAM-2, T-lymphocytes through ICAM-3, neutrophils through MAC-1 and various endogenous glycosylated structures [@pone.0001388-Gordon1]--[@pone.0001388-vanKooyk1]; exogenous ligands include glycosylated moieties on *M. tuberculosis*, *M. leprae*, *Bacillus Calmette-Guérin* (BCG), *Heliobacter pylori*, *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, HIV-1, HIV-2, SIV-1, Dengue virus, Ebola Virus, Cytomegalovirus, Hepatitis C virus, *Schistosoma mansoni*, *Leishmania pifanoi* and *Candida albicans* [@pone.0001388-Tailleux2], [@pone.0001388-Alvarez1]--[@pone.0001388-Tassaneetrithep1] (and reviewed in [@pone.0001388-vanKooyk2]).

DC-SIGN is a major receptor for *M. tuberculosis* on immune cell subsets and has been shown to bind mannosylated lipoarabomannan (ManLAM) present on virulent, but not avirulent, strains of *Mycobacterium spp.* [@pone.0001388-Geijtenbeek2]. This binding can lead to internalization of *M. tuberculosis* and infection of DCs and alveolar macrophages [@pone.0001388-Geijtenbeek4]. DC-SIGN may also have additional roles in suppressing Toll-like receptor (TLR) signaling, thereby influencing Th1/Th2 balance (proinflammatory/anti-inflammatory) and causing *M. tuberculosis*-induced immune suppression [@pone.0001388-Geijtenbeek4], [@pone.0001388-vanKooyk2]. This effect is mediated by ManLAM and increased secretion of ManLAM from Mycobacteria may be crucial to tuberculosis disease progression [@pone.0001388-vanKooyk2].

There has been considerable recent interest in the role of *CD209* variation in human susceptibility to infectious diseases including *M. tuberculosis* and *M. leprae,* HIV-1, and Dengue [@pone.0001388-Barreiro1], [@pone.0001388-Barreiro2]--[@pone.0001388-Sakuntabhai1]. All but the *M. leprae* case-control study found an association of the CD209 -336A/G promoter SNP with infectious disease susceptibility or protection. Martin and colleagues demonstrated that the -336G allele was associated with susceptibility to parenteral but not mucosal HIV-1 infection, although this was not replicated in individuals of recent African descent [@pone.0001388-Martin1]. Sakuntabhai and colleagues found that the -336G allele was protective against Dengue fever versus Dengue hemorrhagic fever, but not against controls [@pone.0001388-Sakuntabhai1]. Barreiro and colleagues found an association between with the -871G and -336A alleles and protection against tuberculosis in South African Cape Coloureds, but not against leprosy in Pakistan [@pone.0001388-Barreiro1], [@pone.0001388-Barreiro2]. Although the *CD209* -871 SNP was found to be the polymorphism most significantly associated with tuberculosis susceptibility in the South African Cape Coloureds, Barreiro and colleagues found that this SNP is not polymorphic in other African countries. The relatively high prevalence of the -871 SNP in the South African Cape Coloureds cases and controls is due to their inherent admixture with European and Asian populations.

Sakuntabhai and colleagues also presented evidence that the *CD209* -336G allele disrupts a potential SP-1-like transcription factor binding site and that this allele is associated with lower *CD209* expression *in vitro* than the ancestral -336A variant [@pone.0001388-Sakuntabhai1]. On the basis of the importance of DC-SIGN in *M. tuberculosis* binding and signaling events, and in an attempt to replicate the findings of Barreiro and colleagues in a larger population, we genotyped the *CD209* -336A/G SNP in five tuberculosis case-control studies from four different sub-Saharan African countries.

Methods {#s2}
=======

Sample Information {#s2a}
------------------

The tuberculosis case control studies from The Gambia (A), Republic of Guinea and Guinea Bissau [@pone.0001388-Bennett1], The Gambia (B) [@pone.0001388-Bellamy1], and Malawi [@pone.0001388-Fitness1] have been previously described in detail. Briefly, tuberculosis case definitions for all studies depended upon confirmation of *M. tuberculosis* positivity by culture, smear, or histology. HIV-1 testing was routinely performed and the percentage of HIV-1 positive individuals among the tuberculosis index cases and controls for the various studies are as follows: The Gambia (A), cases 7.5%, controls 5.2%; Republic of Guinea, cases 9.0%, controls 5.1%; Guinea Bissau, cases 23.8%, controls 16.2%; Malawi, cases 62.2%, controls 33.5%. The Gambia (B) cohort has 330 confirmed HIV-1 negative tuberculosis cases, with an additional 17 cases which were not tested for HIV-1 status. Controls for the various studies were defined as persons without a previous history of tuberculosis and were frequency matched for age, sex and area of residence. A number of clinical correlates of tuberculosis were recorded for the The Gambia (A), Republic of Guinea and Guinea Bissau studies including haemoptysis, duration of cough, degree of sputum positivity, and the presence of cavitation and number of zones affected on chest radiograph. Cavitory tuberculosis status and number of zones affected was determined by radiological analysis by board-certified radiologists.

Informed written consent was obtained from patients or their parents or guardians. Ethical approval was provided by the joint Gambian Government/MRC Ethical Committee, Ministry of Public Health (MINSAP, Guinea-Bissau) and National Ethics Committee, Ministry of Health, Conakry, Republique de Guinee. Human experimentation guidelines of these ministries were followed. Ethical approval for the Malawi study protocol was obtained from the National Health Sciences Research Committee of Malawi and the London School of Hygiene and Tropical Medicine Ethics Committee.

Genotyping techniques {#s2b}
---------------------

DNA extraction from blood was performed using Nucleon II kits (Scotlab Bioscience, Buckingham, UK). DNA concentrations were determined using the PicoGreen™ kit (Invitrogen, Carlsbad, USA). Genotyping was performed utilizing the Sequenom™ system (Sequenom, San Diego, USA) which uses mass spectrometry (MALDI-TOF) to discriminate products by their absolute mass [@pone.0001388-Storm1]. Primer extension was carried out utilizing a DNA primer adjacent to the SNP, and a specific reaction mix of polymerase, dNTPs and one ddNTPs. The extension products were then cleaned up to remove salts and 15nl were spotted onto a 384 SpectroCHIP (Sequenom). This chip was analysed by MALDI-TOF mass spectrometer and the alleles called by weight (in kilodaltons) of the extension products. The *CD209* -871A/G (rs735239) and -336A/G (rs4804803) SNP assays were designed using the SPECTRODESIGNER software (Sequenom). The primers for the *CD209* -871A/G were ACGTTGGATGCTCTGTCTGGGTCCTTTTAC, ACGTTGGATGACAGCAATGAAAAAGCAAAG, GCAAAGTACTAGTACATTTAATAAC and for *CD209* -336A/G were ACGTTGGATGTGTTACACCCCCTCCACTAG, ACGTTGGATGAAAGCAGGAAAGCCAGGAGG, CCCTCCACTAGGGCAAGGGT. The assays were in 384-well plates containing 10 ng of DNA in each well were amplified by a touch-down PCR using Titanium Taq polymerase (Clontech). The touch-down PCR cycling conditions were as follows: 95°C for 15 minutes; 94°C for 20 seconds; 65°C for 30 seconds; 72°C for 30 seconds; steps 2 to 4 repeated for 5 cycles; 94°C for 20 seconds; 58°C for 30 seconds; 72°C for 30 seconds; steps 5 to 7 repeated for 5 cycles; 94°C for 20 seconds; 53°C for 30 seconds; 72°C for 30 seconds; steps 8 to 10 repeated for 38 cycles; final extension at 72°C for 3 minutes.

Statistical analysis {#s2c}
--------------------

Statistical analysis of genotype associations and logistic regression was performed using the program SPSS v14.0. The genotypic and allelic tests of association utilized Pearson\'s chi-square test with the respective degrees of freedom. All statistics are two-tailed. If the unadjusted *P* value was significant then further analysis was carried out using a stepwise forward binary logistic regression correction to adjust for the potential confounding factors of HIV status, age, ethnicity, and sex. Mantel-Haenszel for the combined analysis was performed using SPSS by weighting cases by frequency and stratifying by population. The Gambian (B) study utilizes the Gambian (A) study controls for this Mantel-Haenszel analysis. The Breslow-Day and Tarone\'s tests for homogeneity of odds ratios were found to be non-significant indicating that the odds ratio for each study did not significantly deviate from the overall, combined odds ratio. All control genotype distributions were in Hardy-Weinberg equilibrium (*P*\>0.20).

Results {#s3}
=======

CD209 and association with tuberculosis {#s3a}
---------------------------------------

The *CD209* -871A/G and -336A/G SNPs were initially genotyped in 329 tuberculosis cases and 327 control individuals from The Gambia (study group A) [@pone.0001388-Bennett1]. The *CD209* -871 SNP was found to be polymorphic with controls and cases both having a 2.3% allele frequency (allelic *P* = 0.98) consistent with the Barreiro result [@pone.0001388-Barreiro2] and the HapMap project which found variation at this SNP to be very rare to absent in individuals of African descent. The allelic equivalence between cases and controls and the rarity of this SNP precluded genotyping in further populations. For the CD209 -336A/G SNP, however, an overall genotypic association with clinical tuberculosis was observed for this cohort (3x2χ^2^ = 7.79, *P* = 0.020) ([**Table 1**](#pone-0001388-t001){ref-type="table"}). The -336G allele was significantly under-represented in tuberculosis cases (47.0%) when compared to healthy controls (54.0%) (*P* = 0.010, odds ratio of 0.75 (95%CI 0.61--0.94) ([**Table 2**](#pone-0001388-t002){ref-type="table"}). Logistic regression correction for age, sex, ethnic group and HIV-1 status did not significantly affect this association. Subsequently an additional 347 tuberculosis cases from The Gambia were available for genotyping (study group B), revealing a similar tuberculosis case allele frequency (48.0%) and a significant association when analyzed against the study group A control group [@pone.0001388-Bellamy1].

10.1371/journal.pone.0001388.t001

###### *CD209* -336A/G SNP in Patients Enrolled in Tuberculosis Case Control Studies in Four Countries

![](pone.0001388.t001){#pone-0001388-t001-1}

  Variant      The Gambia   Republic of Guinea   Guinea-Bissau   Malawi                                
  ----------- ------------ -------------------- --------------- -------- ------ ------- ------ ------- ------
  AA              26.7             28.0              22.0         28.3    29.8   32.7    25.5   43.5    38.3
  AG              52.6             48.1              48.0         45.6    46.4   39.5    48.2   42.6    50.5
  GG              20.7             23.9              30.0         26.1    23.8   27.8    26.3   13.9    11.2
  χ^2^            7.79             4.66               --          0.24     --    2.71     --    3.45     --
  *P* value    **0.020**          0.097               --         0.886     --    0.258    --    0.178    --

Genotypic frequency and genotypic association (3×2 χ^2^, 2 degrees of freedom) for *CD209* -336A/G (rs4804803) from 2176 individuals enrolled in tuberculosis case control studies from The Gambia (A), Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B) (ref. 34) and Malawi (ref. 35). Significance level of *P*\<0.05 is indicated in bold.

10.1371/journal.pone.0001388.t002

###### *CD209* -336A/G SNP Allelic Association in Tuberculosis Case Control Studies

![](pone.0001388.t002){#pone-0001388-t002-2}

  Variant              The Gambia (A)   The Gambia (B)\*   Republic of Guinea   Guinea-Bissau     Malawi      Overall (M-H)
  ------------------- ---------------- ------------------ -------------------- --------------- ------------- ---------------
  G allele Controls     353 (54.0%)       353 (54.0%)         142 (47.0%)        142 (50.4%)    215 (36.4%)        --
  G allele Cases        309 (47.0%)       333 (48.0%)         176 (48.9%)        154 (47.5%)    172 (35.2%)        --
  Odds Ratio                0.75              0.79                1.08              0.89           0.95           0.86
  95% CI                 0.61--0.94        0.64--0.97          0.79--1.46        0.65--1.23     0.74--1.22     0.77--0.96
  *P* value              **0.010**         **0.028**             0.632              0.488          0.684        **0.006**

The allelic *P* value for 2176 individuals enrolled in tuberculosis case control studies. The Gambia (A), Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B) (ref. 34) and Malawi (ref. 35). \*The Gambia (B) study utilizes The Gambia (A) controls. Significance levels of *P*\<0.05 are indicated in bold.

Study groups from Republic of Guinea, Guinea-Bissau, and Malawi were then used in an attempt to replicate this finding [@pone.0001388-Bennett1], [@pone.0001388-Lienhardt1]. Each study group, with the exception of Republic of Guinea study, demonstrated the same trend towards a protective effect of the -336G allele. In total 2176 individuals were analyzed in this study and combining the results in a Mantel-Haenszel test predicted a protective effect of the -336G allele with an overall odds ratio of 0.86 (95%CI 0.77--0.96) and *P* = 0.006 ([**Table 2**](#pone-0001388-t002){ref-type="table"}). This allelic model yielded a non-significant homogeneity of odds ratio between all the study groups, (Tarone\'s and Breslow-Day *P* = 0.32), suggesting that there was a good consistency between the combined odds ratio with the individual odds ratios for each study.

Considering that HIV-1 status could potentially confound this association we performed the Mantel-Haenszel test excluding all individuals known to be HIV positive, giving an odds ratio of 0.83 (95%CI 0.73--0.94) and *P* = 0.003 ([**Table S1**](#pone.0001388.s001){ref-type="supplementary-material"}). Although this exclusion of HIV-infected individuals reduces the total sample size of the study the conclusion remains unchanged.

CD209 and clinical correlates of tuberculosis {#s3b}
---------------------------------------------

The *CD209* -336A/G SNP was further examined in the cases for association with clinical correlates of tuberculosis, with no significant difference between sex, HIV status, age, haemoptysis, number of zones affected on chest radiograph, duration of cough or degree of sputum positivity. However, a significant association was obtained between *CD209* -336GG genotype status and lung cavitation in tuberculosis patients. Patients homozygous for the *CD209* -336GG allele were associated with 2.4-fold protection against cavitory tuberculosis disease (n = 557, Pearson\'s 2×2 χ^2^ = 17.34, *P* = 0.00003, odds ratio = 0.42, 95%CI 0.27--0.65, *P* ~Bonferroni\ corrected~ = 1.19×10^−4^)([**Figure 1**](#pone-0001388-g001){ref-type="fig"} and [**Table 3**](#pone-0001388-t003){ref-type="table"}).

![*CD209* -336GG and *M. tuberculosis*-induced lung cavitation.\
This figure describes the percent of individuals with the *CD209* -336GG genotype who presented with cavitory tuberculosis disease.](pone.0001388.g001){#pone-0001388-g001}

10.1371/journal.pone.0001388.t003

###### *CD209* -336A/G and Clinical Correlates of Tuberculosis

![](pone.0001388.t003){#pone-0001388-t003-3}

  Clinical Correlates              Status     *CD209* -336A/G variant[\*](#nt103){ref-type="table-fn"}      Total      *P* value    Odds Ratio     95% CI  
  ----------------------------- ------------ ---------------------------------------------------------- ------------- ----------- --------------- -------- --------------
  Sex                               Male                            573 (73.4%)                          208 (26.6%)      781          0.293       0.871    0.673--1.127
                                   Female                           389 (76.0%)                          123 (24.0%)      512                              
  HIV                             Negative                          831 (73.8%)                          295 (26.2%)     1126          0.255       1.306    0.823--2.073
                                  Positive                           92 (78.6%)                          25 (21.4%)       117                              
  Age Groups                       0--19                            100 (75.8%)                          32 (24.2%)       132          0.996               
                                   20--29                           363 (74.1%)                          127 (25.9%)      490                              
                                   30--39                           264 (74.6%)                          90 (25.4%)       354                              
                                   40--49                           145 (74.4%)                          50 (25.6%)       195                              
                                   50--99                            90 (73.8%)                          32 (26.2%)       122                              
  Haemoptysis                        No                             281 (77.2%)                          83 (22.8%)       364          0.858       0.959    0.604--1.523
                                    Yes                             113 (77.9%)                          32 (22.2%)       145                              
  Cavitation                         No                             194 (69.8%)                          84 (30.2%)       278      **0.0000313**   0.421    0.278--0.636
                                    Yes                             236 (84.6%)                          43 (15.4%)       279                              
  No. Zones affected                1--3                            182 (77.1%)                          54 (22.9%)       236          0.931       0.982    0.658--1.468
                                    4--6                            247 (77.4%)                          72 (22.6%)       319                              
  Duration of cough              0--8 weeks                         271 (79.0%)                          72 (21.0%)       343          0.259       1.285    0.831--1.989
                                 \>8 weeks                          123 (74.5%)                          42 (25.5%)       165                              
  Degree of sputum positivity        \+                              12 (66.7%)                           6 (33.3%)       18           0.604               
                                     ++                             162 (75.7%)                          52 (24.3%)       214                              
                                    +++                             337 (76.8%)                          102 (23.2%)      439                              

Combined West African tuberculosis case control data. Significance level of *P*\<0.05 is indicated in bold.

Discussion {#s4}
==========

There is increasing evidence to support an important role for DC-SIGN in the pathophysiology of a number of infectious diseases, including *M. tuberculosis* infection.

Functional evidence suggests that the -336G variant has lower basal expression of *CD209* when compared to the -336A ancestral allele [@pone.0001388-Sakuntabhai1]. Extrapolation of these *in vitro* experiments to *in vivo CD209* expression suggests that -336G individuals would have lower levels of DC-SIGN on DCs and alveolar macrophages when compared to -336A individuals. Barreiro and colleagues found an association with the -336A allele and protection against tuberculosis and suggest that higher levels of DC-SIGN may be beneficial in protection against tuberculosis disease.

Here we report studies of the *CD209* -336A/G SNP in multiple tuberculosis case control groups based in The Gambia, Republic of Guinea, Guinea-Bissau, and Malawi. These studies, taken together, reveal a genetic association with the -336G allele and protection against tuberculosis. This protection was independent of HIV-1 status as assessed by logistic regression as well as removing all known HIV-1 cases from the analysis ([**Table S1**](#pone.0001388.s001){ref-type="supplementary-material"}). These results differ from the Barrerio study [@pone.0001388-Barreiro2]. This discrepancy could reflect a chance finding in the original single study group, since the confidence interval for this population overlaps with those of our three smaller studies ([**Figure 2**](#pone-0001388-g002){ref-type="fig"}). Barreiro and colleagues studied a South African Coloured population known to have the -871 variant, which was absent in all of the sub-Saharan African populations previously genotyped and very rare (\<2.5%) in this study. Indeed, it was the −871 variant which showed the most compelling evidence of association, with the −336 variant failing to reach even the nominal significance level of *P* = 0.05 after correcting for multiple testing. Due to the relative absence of the −871 variant in the African populations genotyped in this present study we could not ascertain the effect of this variant in susceptibility to tuberculosis and it is entirely possible that the −871/−336 haplotype drives differential *CD209* expression patterns but further work will be needed to confirm this.

![Odds ratio plot (with 95% confidence intervals) for *CD209* -336A/G.\
The odds ratio (with 95% confidence intervals) for *CD209* -336A/G for each of the studies are shown. Studies include the Barreiro study (ref. 30), The Gambia (A) (ref. 33), The Gambia (B) (ref. 34), Republic of Guinea (ref. 33), Guinea-Bissau (ref. 33) and Malawi (ref. 35). The central mark on each line indicates the odds ratio for each study and the line indicates that 95% confidence interval for each. The dashed line indicates the extent of the 95% confidence interval for the combined analysis of the populations analyzed for this study.](pone.0001388.g002){#pone-0001388-g002}

Subgroup analysis suggested a significant association between *CD209* -336GG genotype status and protection against lung cavitation. The potential role of DC-SIGN in cavitory tuberculosis disease is novel and warrants further investigation. In this study we are not able to distinguish between cavitory tuberculosis caused by progression from primary infection, re-infection, or indeed by canonical post-primary reactivation disease. Cavitory tuberculosis in this setting defines a particularly severe manifestation of tuberculosis. Pulmonary cavitation in tuberculosis is known to be associated with the production of Th2 cytokines such as IL-4, which have in turn been demonstrated to result in higher surface expression levels of DC-SIGN in DCs [@pone.0001388-Condos1]--[@pone.0001388-vanCrevel1]. This raises the interesting question of whether individuals homozygous for the -336G allele may, in part, be protected from expressing high levels of DC-SIGN and therefore less prone to the Th2 shift induced by ManLam binding to DC-SIGN [@pone.0001388-Geijtenbeek4], [@pone.0001388-vanKooyk2], [@pone.0001388-Soilleux2], [@pone.0001388-Soilleux3].

Maturation of DCs, defined by DC upregulation of co-stimulatory molecules such as CD80/CD86, can occur on exposure to TLR ligands. This process can however be inhibited by a variety of unknown mechanisms. One possible mechanism of inhibition of DC maturation is the binding of pattern recognition receptors to molecular patterns present on host cells [@pone.0001388-vanKooyk3]. This process, in theory, would cause DC anergy and a reduction in the pro-inflammatory response, even in the presence of pathogen-associated molecular patterns. Virulent *Mycobacterium spp.* have evolved mechanisms to more heavily decorate the cell wall lipoglycoconjugates with α(1→2) mannosylated termini which closely resemble the high mannose N-linked oligosaccharides of newly produced glycoproteins in eukaryotic cells [@pone.0001388-Torrelles1]. Perhaps this molecular mimicry could be part of the mechanism by which virulent strains of *M. tuberculosis* modulate the immune response. If so, DC-SIGN is a prime target for this virulence strategy.

Overall, our results suggest that lower levels of DC-SIGN on immune subsets may be protective against tuberculosis in the sub-Saharan Africa setting. The findings implicate the involvement of DC-SIGN in the pathogenesis of clinical tuberculosis in general, and severe, cavitory tuberculosis in particular. This has wider implications since it provides further evidence that *M. tuberculosis* may use the DC-SIGN receptor to subvert the immune response.
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